givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Intermittent Porphyria
Conditions
Acute Intermittent Porphyria
Trial Timeline
May 6, 2015 → Sep 6, 2017
NCT ID
NCT02452372About givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl)
givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl) is a phase 1 stage product being developed by Alnylam Pharmaceuticals for Acute Intermittent Porphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT02452372. Target conditions include Acute Intermittent Porphyria.
What happened to similar drugs?
20 of 20 similar drugs in Acute Intermittent Porphyria were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02452372 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Intermittent Porphyria